Clinical trial CHRONOS-4
A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin's lymphoma (iNHL)
| Cancers | |
|---|---|
| Organ | Non-Hodgkin lymphoma |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Bayer |
| EudraCT Identifier | 2015-001088-38 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02626455 |
| Inclusion criteria | 2nd to 4th line / at least 1 bi-dimensionaly measurable lesion/ HbA1c |
| Last update |